<?xml version='1.0' encoding='utf-8'?>
<document id="29663428"><sentence text="Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach."><entity charOffset="0-9" id="DDI-PubMed.29663428.s1.e0" text="Midazolam" /></sentence><sentence text="Midazolam is the preferred probe to phenotype cytochrome P450 (CYP) 3A activity"><entity charOffset="0-9" id="DDI-PubMed.29663428.s2.e0" text="Midazolam" /></sentence><sentence text=" This study evaluated a single-concentration, midazolam limited sampling strategy utilizing a population pharmacokinetic (PK) approach to estimate area under the curve, and thus CYP3A activity"><entity charOffset="46-55" id="DDI-PubMed.29663428.s3.e0" text="midazolam" /></sentence><sentence text=" Midazolam concentrations from adults during CYP3A constitutive conditions were obtained from previous studies after single, oral or intravenous administration"><entity charOffset="1-10" id="DDI-PubMed.29663428.s4.e0" text="Midazolam" /></sentence><sentence text=" Population PK modeling was conducted by nonlinear mixed-effects modeling" /><sentence text=" Potential covariates of clearance, volume of distribution, and bioavailability were evaluated" /><sentence text=" A limited sampling model at 1, 2, 4, or 6 hours was selected and fitted with post hoc estimation with the final population PK model" /><sentence text=" Preset criterion for the limited sampling model selection was a coefficient of determination ≥0" /><sentence text="9" /><sentence text=" Bias and precision were also evaluated" /><sentence text=" The studies provided 2122 observations from 152 healthy adults" /><sentence text=" Midazolam concentrations were adequately described by a two-compartment model with first order absorption"><entity charOffset="1-10" id="DDI-PubMed.29663428.s12.e0" text="Midazolam" /></sentence><sentence text=" Age and sex were significant covariates of central volume (V2 ) and were retained in the final model" /><sentence text=" An estimate (interindividual variability) of midazolam clearance was 32"><entity charOffset="46-55" id="DDI-PubMed.29663428.s14.e0" text="midazolam" /></sentence><sentence text="5 L/hr (52" /><sentence text="9%), covariate of central volume was 67 L (39" /><sentence text="1%), and oral bioavailability was 0" /><sentence text="33 (45" /><sentence text="5%)" /><sentence text=" The final population parameter estimates were within the 95% confidence intervals and were similar to the median bootstrap estimates" /><sentence text=" Upon comparison to the population PK model, the 4-hour limited sampling model estimated area under the curve had an acceptable coefficient of determination and acceptable bias and precision limits" /><sentence text=" A 4-hour, but not the 1-, 2-, and 6-hour, single concentration accurately estimated midazolam area under the curve during constitutive CYP3A conditions in healthy adults" /><sentence text="" /></document>